Combining Pharmacological and Cognitive Behavioral Therapy in the Treatment of Anxiety Disorders

Oxford Handbook of Anxiety and Related Disorders

Volumn , Issue , 2008, Pages

  Otto, Michael W ^a   Behar, Evelyn ^b   Smits, Jasper A J ^c   Hofmann, Stefan G ^a  

^a BOSTON UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c SOUTHERN METHODIST UNIVERSITY   (United States)

Author keywords

Cognitive behavioral therapy; Combination treatment; Efficacy; Nonresponse; Pharmacotherapy; Treatment tolerability

Indexed keywords

EID: 84923313934     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/oxfordhb/9780195307030.013.0032     Document Type: Chapter

References (94)

1. Abramowitz, J. S. (1997). Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: A quantitative review. Journal of Consulting and Clinical Psychology, 65, 44-52.
2. Addis, M. E., Hatgis, C., Krasnow, A. D., Jacob, K., Bourne, L., & Mansfield, A. (2004). Effectiveness of cognitivebehavioral treatment for panic disorder versus treatment as usual in a managed care setting. Journal of Consulting and Clinical Psychology, 72, 625-635.
3. Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000). Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. Journal of the American Medical Association, 283, 2529-2536
4. Blomhoff, S., Haug, T. T., Hellström, K., Holme, I., Humble, M., Madsbu, H. P., et al. (2001). Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalized social phobia. British Journal of Psychiatry, 179, 23-30.
5. Bouton, M. E. (2002). Context, ambiguity, and unlearning: Sources of relapse after behavioral extinction. Biological Psychiatry, 52, 976-986.
6. Bouton, M. E., Kenney, F. A., & Rosengard, C. (1990). State dependent fear extinction with two benzodiazepine tranquilizers. Behavioral Neuroscience, 104, 44-55.
7. Cain, C. K., Blouin, A. M., & Barad, M. (2004). Adrenergic transmission facilitates extinction of conditional fear in mice. Learning and Memory, 11, 179-187.
8. Christensen, H., Hadzi-Pavlovic, D. Andrews, G., & Mattick, R. (1987). Behavior therapy and tricyclic medication in the treatment of obsessive-compulsive disorder: A quantitative review. Journal of Consulting and Clinical Psychology, 55, 701-711.
9. Cottraux, J., Mollard, E., Bouvard, M., Marks, I., Sluys, M., Nury, A. M., et al. (1990). A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. International Clinical Psychopharmacology, 5, 17-30.
10. Craske, M. G., Golinelli, D., Stein, M. B., Roy-Byrne, P., Bystritsky, A., & Sherbourne, C. (2005). Does the addition of cognitive behavioral therapy improve panic disorder treatment outcome relative to medication alone in the primarycare setting? Psychological Medicine, 35, 1645-1654.
11. Davidson, J.R.T., Foa, E. B., Huppert, J. D., Keefe, F. J., Franklin, M. E., Compton, J. S., et al. (2004). Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Archives of General Psychiatry, 61, 1005-1013.
12. Davis, M. (2002). Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: Clinical implications for exposure therapy. European Journal of Neuroscience, 16, 395-398.
13. Davis, M., Falls, W. A., & Gewirtz, J. (2000). Neural systems involved in fear inhibition: Extinction and conditioned inhibition. In M. Myslobodsky & I. Weiner (Eds.), Contemporary issues in modeling psychopathology (pp. 113-142). Boston: Kluwer Academic.
14. Davis, M., & Myers, K. M. (2002). The role of glutamate and gamma-aminobutyric acid in fear extinction: Clinical implications for exposure therapy. Biological Psychiatry, 52, 998-1007.
15. Deacon, B. J., & Abramowitz, J. S. (2004). Cognitive and behavioral treatments for anxiety disorders: A review of meta-analytic findings. Journal of Clinical Psychology, 60, 429-441.
16. Deacon, B. J., & Abramowitz, J. S. (2005). Patients' perceptions of pharmacological and cognitive-behavioral treatments for anxiety disorders. Behavior Therapy, 36, 139-145.
17. De Beurs, E., van Balkom, A. J., Lange, A., Koele, P., & van Dyke, R. (1995). Treatment of panic disorder with agoraphobia: Comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. American Journal of Psychiatry, 152, 683-691.
18. D'Souza, D. C., Gil, R., Cassello, K., Morrissey, K., Abi-Saab, D., White, J., et al. (2000). IV glycine and oral Dcycloserine effects on plasma and CSF amino acids in healthy humans. Biological Psychiatry, 47, 450-462.
19. Fava, G. A., Savron, G., Zielezny, M., Grandi, S., Rafanelli, C., & Conti, S. (1997). Overcoming resistance to exposure in panic disorder with agoraphobia. Acta Psychiatrica Scandinavica, 95, 306-312.
20. Foa, E. B., Franklin, M. E., & Moser, J. (2002). Context in the clinic: How well do cognitive-behavioral therapies and medications work in combination? Biological Psychiatry, 10, 987-997.
21. Foa, E. B., & Kozak, M. J. (1986). Emotional processing of fear: Exposure to corrective information. Psychological Bulletin, 99, 20-35.
22. Foa, E. B., Liebowitz, M. R., Kozak, M. J., Davies, S., Campeas, R., Franklin, M. E., et al. (2005). Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. American Journal of Psychiatry, 162, 151-161.
23. Franklin, M. E., Abramowitz, J. S., Bux, D. A., Zoellner, L. A., & Feeny N. C. (2002). Cognitive-behavioral therapy with and without medication in the treatment of obsessive-compulsive disorder. Professional Psychology: Research and Practice, 33, 162-168.
24. Furukawa, T. A., Watanabe, N., & Churchill, R. (2006). Psychotherapy plus antidepressant for panic disorder with or without agoraphobia. British Journal of Psychiatry, 188, 305-312.
25. Goisman, R. M., Warshaw, M. G., & Keller, M. B. (1999). Psychosocial treatment prescriptions for generalized anxiety disorder, panic disorder, and social phobia, 1991-1996. American Journal of Psychiatry, 156, 1819-1821.
26. Gould, R. A., Buckminster, S., Pollack, M. H., Otto, M. W., & Yap, L. (1997a). Cognitive-behavioral and pharmacological treatment for social phobia: A metaanalysis. Clinical Psychology: Science and Practice, 4, 291-306.
27. Gould, R. A., Otto, M. W., & Pollack, M. H. (1995). A meta-analysis of treatment outcome for panic disorder. Clinical Psychology Review, 15, 819-844.
28. Gould, R. A., Otto, M. W., Pollack, M. P., & Yap, L. (1997b). Cognitive-behavioral and pharmacological treatment of generalized anxiety disorder: A preliminary metaanalysis. Behavior Therapy, 28, 285-305.
29. Gronwall, D. M. (1977). Paced auditory serial-addition task: A measure of recovery from concussion. Perceptual & Motor Skills, 44, 367-373.
30. Haug, T. T., Blomhoff, S., Hellström, K., Holme, I., Humble, M., Madsbu, H. P., et al. (2003). Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. British Journal of Psychiatry, 182, 312-318.
31. Hegel, M. T., Ravaris, C. L., & Ahles, T. A. (1994). Combined cognitive-behavioral and time-limited alprazolam treatment of panic disorder. Behavior Therapy, 25, 183-195.
32. Heimberg, R. G., Liebowitz, M. R., Hope, D. A., Schneier, F. R., Holt, C. S., Welkowitz, L. A., et al. (1998). Cognitive behavioral group therapy vs. phenelzine therapy for social phobia: 12-week outcome. Archives of General Psychiatry, 55, 1133-1141.
33. Heresco-Levy, U., Kremer, I., Javitt, D. C., Goichman, R., Reshef, A., Blanaru, M., et al. (2002). Pilotcontrolled trial of D-cycloserine for the treatment of posttraumatic stress disorder. International Journal of Neuropsychopharmacology, 5, 301-307.
34. Herry, C., & Garcia, R. (2002). Prefrontal cortex long-term potentiation, but not long-term depression, is associated with the maintenance of extinction of learned fear in mice. Journal of Neuroscience, 22, 577-583.
35. Heuzenroeder, L., Donnelly, M., Haby, M. M., Mihalopoulos, C., Rossell, R., Carter, R., et al. (2004). Costeffectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder. Australian and New Zealand Journal of Psychiatry, 38, 602-612.
36. Hofmann, S. G., Meuret, A. E., Smits, J.A.J., Simon, N. M., Pollack, M. H., Eisenmenger, K., et al. (2006). Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Archives of General Psychiatry, 63, 298-304.
37. Hohagen, F., Winkelmann, G., Räsche-Rauschle, H., Hand, I., König, A., Münchau, N., et al. (1998). Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo: Results of a multicentre study. British Journal of Psychiatry, 35 (Suppl.), 71-78.
38. Kamphuis, J. H., & Telch, M. J. (2000). Effect of distraction and guided threat reappraisal on fear reduction during exposure-based treatments for specific fears. Behaviour Research and Therapy, 38, 1163-1181.
39. Kampman, M., Keijsers, G. P., Hoogduin, C. A., & Hendriks, G. J. (2002). A randomized, double-blind, placebocontrolled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. Journal of Clinical Psychiatry, 63, 772-777.
40. Kobak, K. A., Greist, J. H., Jefferson, J. W., Katzelnick, D. J., & Henk, H. J. (1998). Behavioral versus pharmacological treatments of obsessive compulsive disorder: A meta-analysis. Psychopharmacology, 136, 205-216.
41. Kushner, M. G., Kim, S. W., Donahue, C., Thuras, P., Adson, D., Kotlyar, M., et al. (2007). Biological Psychiatry, 62, 835-838.
42. Ledgerwood, L., Richardson, R., & Cranney, J. (2005). D-cycloserine facilitates extinction of learned fear: Effects of reacquisition and generalized extinction. Biological Psychiatry, 57, 841-847.
43. Liebowitz, M. R., Heimberg, R. G., Schneier, F., Hope, D. A., Davies, S., Holt, C. S., et al. (1999). Cognitivebehavioral group therapy versus phenelzine in social phobia: Long term outcome. Depression and Anxiety, 10, 89-98.
44. Lydiard, R. B., Brawman-Mintzer, O., & Ballenger, J. C. (1996). Recent developments in the psychopharmacology of anxiety disorders. Journal of Consulting and Clinical Psychology, 64, 660-668.
45. Marks, I. M., Lelliott, P., Basoglu, M., Noshirvani, H., Monteiro, W., Cohen, D., et al. (1988). Clomipramine, selfexposure and therapist-aided exposure for obsessive-compulsive rituals. British Journal of Psychiatry, 152, 522-534.
46. Marks, I. M., Swinson, R. P., Basaglu, M., Kuch, K., Nasirvani, H., O'Sullivan, G., et al. (1993). Alprazolam and exposure alone and combined in panic disorder with agoraphobia: A controlled study in London and Toronto. British Journal of Psychiatry, 162, 776-787.
47. Mavissakalian, M., & Michelson, L. (1986). Agraophobia: Relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine. Journal of Clinical Psychiatry, 47, 117-122.
48. Mavissakalian, M., & Perel, J. M. (1992). Clinical experience in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Archives of General Psychiatry, 49, 318-323.
49. Mavissakalian, M., & Perel, J. M. (1999). Long term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Archives of General Psychiatry, 56, 821-827.
50. Milad, M. R., & Quirk, G. J. (2002). Neurons in medial prefrontal cortex signal memory for fear extinction. Nature, 420, 70-74.
51. Mitte, K. (2005a). Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: A comparison with pharmacotherapy. Psychological Bulletin, 131, 185-195.
52. Mitte, K. (2005b). A meta-analysis of the efficacy of psycho-and pharmacotherapy in panic disorder with and without agoraphobia. Journal of Affective Disorders, 88, 27-45.
53. Morgan, M. A., Romanski, L. M., & LeDoux, J. E. (1993). Extinction of emotional learning: Contribution of medial prefrontal cortex. Neuroscience Letters, 163, 109-113.
54. Mystkowski, J. L., Mineka, S., Vernon, L. L., & Zinbarg, R. E. (2003). Changes in caffeine states enhance return of fear in spider phobia. Journal of Consulting and Clinical Psychology, 71, 243-250.
55. Noyes, R., Garvey, M. J., Cook, B., & Suelzer, M. (1991). Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. American Journal of Psychiatry, 148, 517-523.
56. Otto, M. W. (1992). Normal and abnormal information processing: A neuropsychological perspective on obsessive compulsive disorder. Psychiatric Clinics of North America, 15, 825-847.
57. Otto, M. W., Basden, S., Leyro, T. M., McHugh, R. K., & Hofmann, S. G. (2007). Clinical perspectives on the combination of D-cycloserine and CBT for the treatment of anxiety disorders. CNS Spectrums, 12, 51-61.
58. Otto, M. W., Hinton, D., Korbly, N. B., Chea, A., Phalnarith, B., Gershuny, B. S., et al. (2003). Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: A pilot study of combination treatment with cognitive-behavior therapy vs. sertraline alone. Behaviour Research and Therapy, 41, 1271-1276.
59. Otto, M. W., Penava, S. J., Pollock, R. A., & Smoller, J. W. (1996). Cognitive-behavioral and pharmacologic perspectives on the treatment of posttraumatic stress disorder. In M. H. Pollack, M. W. Otto, & J. F. Rosenbaum (Eds.), Challenges in clinical practice: Pharmacologic and psychosocial strategies (pp. 219-260). New York: Guilford Press.
60. Otto, M. W., Pollack, M. H., & Maki, K. M. (2000). Empirically-supported treatment for panic disorder: Costs, benefits, and stepped care. Journal of Consulting and Clinical Psychology, 68, 556-563.
61. Otto, M. W., Pollack, M. H., Penava, S. J., & Zucker, B. G. (1999). Cognitive-behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: A clinical case series. Behaviour Research and Therapy, 37, 763-770.
62. Otto, M. W., Pollack, M. H., & Sabatino, S. A. (1996). Maintenance of remission following cognitive-behavior therapy for panic disorder: Possible deleterious effects of concurrent medication treatment. Behavior Therapy, 27, 473-482.
63. Otto, M. W., Pollack, M. H., Sachs, G. S., Reiter, S. R., Meltzer-Brody, S., & Rosenbaum, J. F. (1993). Discontinuation of benzodiazepine treatment: Efficacy of cognitive-behavior therapy for patients with panic disorder. American Journal of Psychiatry, 150, 1485-1490.
64. Otto, M. W., Safren, S. A., Nicolaou, D. C., & Pollack, M. H. (2003). Considering mechanisms of action in the treatment of social anxiety disorder. In M. H. Pollack, N. M. Simon, and M. W. Otto (Eds.), Social phobia: Presentation, course, and treatment. New York: Castle Connolly Graduate Medical Publishing.
65. Otto, M. W., Smits, J.A.J., & Reese, H. E. (2004). Cognitive-behavioral therapy for the treatment of anxiety disorders. Journal of Clinical Psychiatry, 65 (Suppl. 5), 34-41.
66. Otto, M. W., Tuby, K. S., Gould, R. A., McLean, R. Y., Pollack, M. H. (2001). An effectsize analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. American Journal of Psychiatry, 158 (12), 1989-1992.
67. Park, J. M., Mataix-Cols, D., Marks, I. M., Ngamthipwatthana, T., Marks, M., Araya, R., et al. (2001). Two-year followup after a randomised controlled trial of self- and clinician-accompanied exposure for phobia/panic disorders. British Journal of Psychiatry, 178, 543-548.
68. Parnas, A. S., Weber, M., & Richardson, R. (2005). Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiology of Learning and Memory, 83, 224-231.
69. Penava, S. J., Otto, M. W., Maki, K. M., & Pollack, M. H. (1998). Rate of improvement during cognitive-behavioral group treatment for panic disorder. Behaviour Research and Therapy, 36, 665-673.
70. Pollack, M. H. (2005). The pharmacotherapy of panic disorder. Journal of Clinical Psychiatry, 66 (Suppl. 4), 23-27.
71. Pollack, M. H., Otto, M. W., Kaspi, S. P., Hammerness, P. G., & Rosenbaum, J. F. (1994). Cognitive-behavior therapy for treatment-refractory panic disorder. Journal of Clinical Psychiatry, 55, 200-205.
72. Powers, M. B., Smits, J.A.J., Leyro, T. M., & Otto, M. (2006). Translational research perspectives on maximizing the effectiveness of exposure therapy. In D.C.S. Richard and D. Lauterbach (Eds.), Comprehensive handbook of the exposure therapies (pp. 109-126). Burlington, MA: Academic Press.
73. Powers, M. B., Smits, J. A., & Telch, M. J. (2004). Disentangling the effects of safety-behavior utilization and safetybehavior availability during exposure-based treatment: A placebo-controlled trial. Journal of Consulting and Clinical Psychology, 72, 448-454.
74. Quartermain, D., Mower, J., Rafferty, M. F., Herting, R. L., & Lanthorn, T. H. (1994). Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. European Journal of Pharmacology, 157, 7-12.
75. Quirk, G. J., Russo, G. K., Barron, J. L., & Lebron, K. (2000). The role of ventromedial prefrontal cortex in the recovery of extinguished fear. Journal of Neuroscience, 20, 6225-6231.
76. Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., et al. (2004). Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobics to facilitate extinction of fear. Archives of General Psychiatry, 61, 1136-1144.
77. Richardson, R., Ledgerwood, L., & Cranney, J. (2004). Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. Learning and Memory, 11, 510-516.
78. Rodriguez, B. I., & Craske, M. G. (1993). The effects of distraction during exposure to phobic stimuli. Behaviour Research and Therapy, 31, 549-558.
79. Schmidt, N. B., Wollaway-Bickel, K., Trakowski, J. H., Santiago, H. T., & Vasey, M. (2002). Antidepressant discontinuation in the context of cognitive behavioral treatment for panic disorder. Behaviour Research and Therapy, 40, 67-73.
80. Siegle, G. J., Ghinassi, F., & Thase, M. E. (in press). Neurobehavioral therapies in the 21st century: Summary of an emerging field and an extended example of cognitive control training for depression. Cognitive Therapy and Research.
81. Sloan, T., & Telch, M. J. (2002). The effects of safety-seeking behavior and guided threat reappraisal on fear reduction during exposure: An experimental investigation. Behaviour Research and Therapy, 40, 235-251.
82. Spiegel, D. A., Bruce, T. J., Gregg, S. F., & Nuzzarello, A. (1994). Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? American Journal of Psychiatry, 151, 876-881.
83. Stein, D. J., Versiani, M., Hair, T., & Kumar, R. (2002). Efficacy of paroxetine for relapse prevention in social anxiety disorder: A 24-week study. Archives of General Psychiatry, 59, 1111-1118.
84. Stein, M. B., Sherbourne, C. D., Craske, M. G., Means-Christensen, A., Bystritsky, A., Katon, W., et al. (2004). Quality of care for primary care patients with anxiety disorders. American Journal of Psychiatry, 161, 2230-2237.
85. Stuart, G. L., Treat, T. A., & Wade, W. A. (2000). Effectiveness of an empirically based treatment for panic disorder delivered in a service clinic setting: 1-year follow-up. Journal of Consulting and Clinical Psychology, 68, 506-512.
86. Sutherland, S. M., & Davidson, J.R.T. (1995). β-Blockers and benzodiazepines in pharmacotherapy. In M. B. Stein (Ed.), Social phobia: Clinical and research perspectives (pp. 323-326). Washington, DC: American Psychiatric Press.
87. Telch, M. J., Agras, W. S., Taylor, C. B., Roth, W. T., & Gallen, C. (1985). Combined pharmacological and behavioral treatment for agoraphobia. Behaviour Research and Therapy, 23, 325-335.
88. Van Balkom, A. J., de Haan, E., van Oppen, P., Spinhoven, P., Hoogduin, K. A., & van Dyck, R. (1998). Cognitive and behavioral therapies alone and in combination with fluvoxamine in the treatment of obsessive-compulsive disorder. Journal of Nervous and Mental Disease, 186, 492-499.
89. Van Berckel, B. N., Lipsch, C., Gispende Wied, C., Wynne, H. J., Blankenstein, M. A., van Ree, J. M., et al. (1998). The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers. Psychopharmacology (Berl), 138, 190-197.
90. Van Etten, M. L., & Taylor, S. (1998). Comparative efficacy of treatments for posttraumatic stress disorder: A metaanalysis. Clinical Psychology and Psychotherapy, 5, 126-144.
91. Wade, W. A., Treat, T. A., & Stuart, G. L. (1998). Transporting an empirically supported treatment for panic disorder to a service clinic setting: A benchmarking strategy. Journal of Consulting and Clinical Psychology, 66, 231-239.
92. Walker, J. R., Van Ameringen, M. A., Swinson, R., Bowen, R. C., Chokka, P. R., Goldner, E., et al. (2000). Prevention of relapse in generalized social phobia: Results of a 24-week study in responders to 20 weeks of sertraline treatment. Journal of Clinical Psychopharmacology, 20,636-644.
93. Wells, A. (2000). Emotional disorders and metacognition: Innovative cognitive therapy. New York: Wiley.
94. Whittal, M. L., Otto, M. W., & Hong, J. J. (2001). Cognitive-behavior therapy for discontinuation of SSRI treatment of panic disorder: A case series. Behaviour Research and Therapy, 39, 939-945.